# CardioFocus

CardioFocus is an Asset Manager based in Marlborough, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Marlborough, United States
- **Region:** North America
- **Address:** 500 Nickerson Road, Marlborough, MA 01752, United States
- **Assets under management:** Undisclosed
- **Website:** cardiofocus.com
- **LinkedIn:** https://www.linkedin.com/company/cardiofocus

## Regulatory record

- **Reports private funds:** No

## About

CardioFocus develops pulsed field ablation (PFA) systems for treating atrial fibrillation, co-engineering catheters and generators as an integrated therapy platform. Its portfolio includes the Centauri System, the QuickShot Nav focal catheter, the OptiShot balloon catheter, and the CardioWave generator. The company emphasizes waveform science and catheter integration to enable precise, repeatable lesion formation.

## Sectors

- Medical Devices
- Cardiology

## People

- Burke T. Barrett — Chief Executive Officer

## Questions

### Who runs investment decisions at CardioFocus?

CardioFocus is an operating company, not an investment manager or family office. Capital-allocation and R&D-prioritization decisions sit with Chief Executive Officer Burke T. Barrett and the leadership team listed on the firm's website, which includes heads of Finance and Administration, Engineering, and Business Development. The board composition that governs those decisions is not publicly disclosed.

### What is CardioFocus's current product focus, and how did it evolve?

The company originally gained FDA approval for its HeartLight laser-balloon ablation system in 2016 and treated more than 10,000 patients with that technology. Since 2024 it has pivoted almost entirely to pulsed field ablation (PFA), acquiring the electrophysiology division of Galvanize Therapeutics to bring in the Centauri generator and advancing three additional proprietary PFA catheters: QuickShot Nav, OptiShot, and the CardioWave system.

### Does CardioFocus collaborate with robotic-navigation platforms?

Yes. In October 2025 CardioFocus announced a collaboration with Stereotaxis to advance robotic pulsed field ablation for cardiac arrhythmias. The partnership aims to integrate Stereotaxis's robotic magnetic navigation with CardioFocus's PFA catheters, targeting electrophysiology labs that already use robotic workflows.

## Related profiles

- [MadCap Software](https://altss.com/profile/madcap-software)
- [ImageQuix](https://altss.com/profile/imagequix)

---

Last updated: 2026-07-10T21:16:07.000Z

Canonical page: https://altss.com/profile/cardiofocus

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology